apremilast psoriatic arthritis in athletes

Keyword	CPC	PCC	Volume	Score	Length of keyword
apremilast psoriatic arthritis in athletes	0.22	0.9	7027	56	42
apremilast	0.7	0.5	4310	4	10
psoriatic	0.32	0.9	8091	72	9
arthritis	0.08	1	5311	19	9
in	1.4	0.1	4462	78	2
athletes	1.1	1	3446	65	8

Keyword	CPC	PCC	Volume	Score
apremilast psoriatic arthritis in athletes	1.55	0.9	519	68

Search Results related to apremilast psoriatic arthritis in athletes on Search Engine

Treatment of psoriatic arthritis with biologic and targeted
oup.com

https://academic.oup.com/rheumatology/article/60/4/1588/5937237

WEBOct 23, 2020 · American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis . British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 . Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (2010) NICE Technology Appraisal Guidance 199

DA: 41 PA: 14 MOZ Rank: 5

Apremilast for athletes: Side effects, risks, and safety
medicalnewstoday.com

https://www.medicalnewstoday.com/articles/apremilast-psoriatic-arthritis-in-athletes

WEBMay 24, 2022 · Apremilast treats inflammation and can relieve the symptoms of psoriatic arthritis. It is not unsafe for athletes, but the side effects may affect performance. Learn more here.

DA: 98 PA: 17 MOZ Rank: 70

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317912/

WEBMay 8, 2020 · INTRODUCTION. Apremilast, an oral phosphodiesterase 4 inhibitor, has demonstrated clinical improvements in patients with active psoriatic arthritis (PsA), including signs, symptoms, and quality of life, and was generally well tolerated in the phase 3, randomized Psoriatic Arthritis Long‐term Assessment of Clinical Efficacy (PALACE) …

DA: 95 PA: 72 MOZ Rank: 21

Long-term experience with apremilast in patients with
biomedcentral.com

https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-1901-3

WEBMay 10, 2019 · Background The efficacy and safety of apremilast were assessed in patients with psoriatic arthritis (PsA) in three phase III clinical trials with similar designs (PALACE 1, 2, and 3). Methods Following a 24-week, randomized (1:1:1 to apremilast 30 mg twice daily, 20 mg twice daily, or placebo), double-blind phase and a 28-week …

DA: 31 PA: 91 MOZ Rank: 94

Apremilast - StatPearls - NCBI Bookshelf
nih.gov

https://www.ncbi.nlm.nih.gov/books/NBK572078/

WEBJul 10, 2023 · Apremilast is FDA approved for treating psoriatic arthritis in adult patients with moderately to severely active disease, plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy, and adults with Behcet disease associated with oral ulcers. It is a small molecule phosphodiesterase 4 (PDE4) inhibitor. Apremilast …

DA: 17 PA: 79 MOZ Rank: 85

Apremilast in the treatment of psoriatic arthritis: a
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315225/

WEBJan 20, 2017 · Abstract. Apremilast is an orally-active small molecule which inhibits phosphodiesterase-4 (PDE4). Clinical trials have demonstrated its efficacy and safety in psoriatic arthritis (PsA) and psoriasis. Established therapeutic options have variable effectiveness across the different domains of psoriatic disease.

DA: 49 PA: 3 MOZ Rank: 50

Expert recommendations for the use of apremilast in psoriatic
sciencedirect.com

https://www.sciencedirect.com/science/article/pii/S2173574322000922

WEBJan 1, 2023 · Introduction. Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with a significant decline in function and quality of life 1.Patients with PsA are at increased risk of obesity, insulin resistance, type 2 diabetes mellitus, hypertension, hyperlipidaemia, and cardiovascular disease 2.

DA: 1 PA: 79 MOZ Rank: 59

Apremilast: welcome advance in treatment of psoriatic arthritis
nature.com

https://www.nature.com/articles/nrrheum.2014.77

WEBMay 20, 2014 · The US FDA has recently given approval for the use of apremilast (Otezla ®, Celgene, USA), an oral phosphodiesterase-4 (PDE-4) inhibitor, in adults with active psoriatic arthritis (PsA). 1 For a ...

DA: 39 PA: 10 MOZ Rank: 20

Long-term safety and tolerability of apremilast in patients
jaad.org

https://www.jaad.org/article/S0190-9622(17)30146-9/fulltext

WEBApr 14, 2017 · Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2) - Journal of the …

DA: 52 PA: 2 MOZ Rank: 84

Long-term experience with apremilast in patients with
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509758/

WEBMay 10, 2019 · Apremilast, an oral phosphodiesterase 4 inhibitor, has been proven effective in patients with psoriatic arthritis (PsA) [1–3]. Apremilast was studied for the treatment of PsA in three similarly designed, phase III studies (Psoriatic Arthritis Long-term Assessment of Clinical Efficacy [PALACE] 1, 2, and 3) that enrolled disease …

DA: 11 PA: 94 MOZ Rank: 10

Expert recommendations for the use of apremilast in psoriatic
nih.gov

https://pubmed.ncbi.nlm.nih.gov/35537933/

WEBIntroduction and objectives: Despite the evidence, there are doubts about the positioning of apremilast in the psoriatic arthritis (PsA) treatment algorithm. The objective of this project was to collect the scientific evidence and the experience of a group of rheumatologists who are experts in the management of PsA with apremilast in clinical practice in Spain.

DA: 28 PA: 8 MOZ Rank: 39

Apremilast: A Review in Psoriasis and Psoriatic Arthritis
springer.com

https://link.springer.com/article/10.1007/s40265-017-0709-1

WEBFeb 18, 2017 · Apremilast (Otezla®) is an orally administered, small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate to severe plaque psoriasis in the phase 3 ESTEEM trials, as well as improving difficult-to-treat nail, scalp and palmoplantar psoriasis. Most patient-reported outcomes, …

DA: 12 PA: 57 MOZ Rank: 77